Headlines about Beigene (NASDAQ:BGNE) have been trending somewhat positive this week, Accern Sentiment Analysis reports. The research group identifies negative and positive news coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Beigene earned a coverage optimism score of 0.07 on Accern’s scale. Accern also assigned headlines about the company an impact score of 44.1617851714262 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.

Here are some of the headlines that may have effected Accern’s analysis:

A number of brokerages recently weighed in on BGNE. BidaskClub downgraded shares of Beigene from a “buy” rating to a “hold” rating in a research note on Saturday, January 13th. Zacks Investment Research downgraded shares of Beigene from a “hold” rating to a “sell” rating in a research note on Monday, January 8th. Cowen reissued a “buy” rating on shares of Beigene in a research note on Monday, January 8th. Maxim Group set a $120.00 target price on shares of Beigene and gave the stock a “buy” rating in a research note on Wednesday, January 3rd. Finally, ValuEngine downgraded shares of Beigene from a “hold” rating to a “sell” rating in a research note on Wednesday, January 3rd. Two research analysts have rated the stock with a sell rating, two have given a hold rating and six have assigned a buy rating to the company. Beigene currently has a consensus rating of “Hold” and a consensus price target of $96.67.

Beigene (NASDAQ:BGNE) traded down $2.89 on Friday, reaching $112.67. 455,194 shares of the company’s stock traded hands, compared to its average volume of 224,367. Beigene has a 12-month low of $31.74 and a 12-month high of $119.60. The company has a current ratio of 9.33, a quick ratio of 9.27 and a debt-to-equity ratio of 0.20. The company has a market capitalization of $5,122.77, a P/E ratio of -86.67 and a beta of -1.03.

Beigene (NASDAQ:BGNE) last posted its quarterly earnings results on Monday, November 13th. The company reported $2.54 earnings per share for the quarter, beating the consensus estimate of $0.23 by $2.31. The company had revenue of $220.21 million during the quarter, compared to the consensus estimate of $1.55 million. During the same period last year, the firm posted ($1.08) earnings per share. analysts forecast that Beigene will post -2.04 earnings per share for the current fiscal year.

In other news, CEO John Oyler sold 150,957 shares of the business’s stock in a transaction dated Wednesday, November 15th. The shares were sold at an average price of $80.50, for a total transaction of $12,152,038.50. Following the completion of the sale, the chief executive officer now directly owns 491,891 shares of the company’s stock, valued at $39,597,225.50. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CMO Jane Huang sold 1,600 shares of the business’s stock in a transaction dated Monday, November 20th. The stock was sold at an average price of $86.25, for a total transaction of $138,000.00. Following the sale, the chief marketing officer now directly owns 264,900 shares of the company’s stock, valued at $22,847,625. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 483,482 shares of company stock valued at $42,139,474. Insiders own 19.90% of the company’s stock.

WARNING: “Somewhat Favorable Press Coverage Somewhat Unlikely to Affect Beigene (BGNE) Share Price” was first posted by TheOlympiaReport and is owned by of TheOlympiaReport. If you are viewing this report on another domain, it was illegally copied and reposted in violation of U.S. & international copyright & trademark legislation. The correct version of this report can be read at https://theolympiareport.com/2018/01/22/somewhat-favorable-press-coverage-somewhat-unlikely-to-affect-beigene-bgne-share-price.html.

Beigene Company Profile

BeiGene, Ltd. is a clinical-stage biopharmaceutical company. The Company is focused in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. The Company had used its cancer biology platform to develop four clinical-stage drug candidates, such as BGB-3111, BGB-A317, BGB-290 and BGB-283, as of December 31, 2016.

Insider Buying and Selling by Quarter for Beigene (NASDAQ:BGNE)

Receive News & Ratings for Beigene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beigene and related companies with MarketBeat.com's FREE daily email newsletter.